字号·· | 护眼
罗塞塔简报

GLP-1类药物临床试验加速拓展 延伸至成瘾、衰老及心脏病等新领域GLP-1类药物临床试验加速拓展 延伸至成瘾、衰老及心脏病等新领域

点「原文对照」整页切到原文,或双击某段只看那段的原文。

对美国ClinicalTrials.gov注册库的分析显示,GLP-1和肠促胰岛素类药物(如Ozempic、Wegovy和Mounjaro)的临床试验正日益瞄准糖尿病和减重以外的疾病。

Clinical Trials for GLP-1 Drugs Expand Rapidly Beyond Diabetes into Addiction, Aging, and Heart Disease alysis of the U.S. ClinicalTrials.gov registry reveals that clinical trials for GLP-1 and incretin drugs—such as Ozempic, Wegovy, and Mounjaro—are increasingly targeting diseases beyond diabetes and weight loss.

虽然糖尿病和肥胖症仍占约1800项已登记试验的大多数,但针对其他病症的试验占比在过去15年里已增至约四分之一的新增试验,增长了两倍。

While diabetes and obesity still account for the majority of the roughly 1,800 registered trials, the share targeting other conditions has tripled over the past 15 years to approximately one in four new trials.

正在进行的中期研究包括:美国退伍军人事务部主导的司美格鲁肽治疗酒精使用障碍试验、伦敦帝国学院的阿尔茨海默病研究、荷兰的心力衰竭研究、纽约的生物衰老试验,以及中国的肝病研究。

Active mid-stage investigations include semaglutide for alcohol use disorder led by the U.S. Department of Veterans Affairs, Alzheimer's research at Imperial College London, heart failure studies in the Netherlands, and biological aging trials in New York, alongside liver disease studies in China.

阅读媒体原文 ↗